These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
87. On the interaction of the first complement component C1 and its subunit C1q with solid-phase IgM immune complexes. Weiner EM Scand J Immunol; 1988 Oct; 28(4):425-30. PubMed ID: 2461584 [TBL] [Abstract][Full Text] [Related]
88. Fibronectin binding with immunoglobulin aggregates and its association with rheumatic disorders. Carter SD; Scott DL; Elson CJ Br J Rheumatol; 1986 Nov; 25(4):353-8. PubMed ID: 3490895 [TBL] [Abstract][Full Text] [Related]
89. Circulating immune complexes in the sera and ascites of hepatocellular carcinoma or chronic hepatitis patients. Chen YM; Hu CP; Wong FH; Chen PH; Tsai YT; Lee SD; Liu JD; Chang CM Zhonghua Min Guo Wei Sheng Wu Ji Mian Yi Xue Za Zhi; 1986 Feb; 19(1):34-45. PubMed ID: 3028719 [TBL] [Abstract][Full Text] [Related]
90. Evidence for the binding of human serum amyloid P component to Clq and Fab gamma. Bristow CL; Boackle RJ Mol Immunol; 1986 Oct; 23(10):1045-52. PubMed ID: 3099175 [TBL] [Abstract][Full Text] [Related]
91. The formation of insoluble immune complexes between ovalbumin and anti-ovalbumin IgG occurs in at least two distinct phases dependent on reactant concentration and ionic strength. Gorgani NN; Easterbrook-Smith SB; Altin JG Biochim Biophys Acta; 1996 Oct; 1317(1):45-54. PubMed ID: 8876626 [TBL] [Abstract][Full Text] [Related]
92. In vivo degradation of rat C1q induced by intravenous injection of soluble IgG aggregates. Veerhuis R; van Es LA; Daha MR Immunology; 1985 Apr; 54(4):801-10. PubMed ID: 3872261 [TBL] [Abstract][Full Text] [Related]
93. Characterization of immune complexes detected by the 125I-C1q binding assay in breast cancer. Krieger G; Kneba M; Bolz I; Nagel GA Clin Immunol Immunopathol; 1988 Jan; 46(1):14-23. PubMed ID: 3257175 [TBL] [Abstract][Full Text] [Related]
94. Characterization of C1q-binding IgG complexes in systemic lupus erythematosus. Uwatoko S; Aotsuka S; Okawa M; Egusa Y; Yokohari R; Aizawa C; Suzuki K Clin Immunol Immunopathol; 1984 Jan; 30(1):104-16. PubMed ID: 6421520 [TBL] [Abstract][Full Text] [Related]
95. The interaction of human plasma fibronectin with a subunit of the first component of complement, C1q. Pearlstein E; Sorvillo J; Gigli I J Immunol; 1982 May; 128(5):2036-9. PubMed ID: 6801128 [TBL] [Abstract][Full Text] [Related]
96. Antibody density on rat red cells determines the rate of activation of the complement component C1. Hughes-Jones NC; Gorick BD; Howard JC; Feinstein A Eur J Immunol; 1985 Oct; 15(10):976-80. PubMed ID: 2996908 [TBL] [Abstract][Full Text] [Related]
97. Differences among immune complexes: association of C1q in SLE immune complexes with renal disease. Greisman SG; Redecha PB; Kimberly RP; Christian CL J Immunol; 1987 Feb; 138(3):739-45. PubMed ID: 3492531 [TBL] [Abstract][Full Text] [Related]
98. Circulating immune complexes in the serum of diabetes mellitus in childhood by a modified 125I-C1q binding test. Nagaoka K; Chinen Y; Takegami T; Nabeya N; Sakurami T; Imura H; Kuno S; Tasaka K; Hamajima Y Endocrinol Jpn; 1979 Oct; 26(5):527-32. PubMed ID: 316767 [TBL] [Abstract][Full Text] [Related]
99. Antibodies to the collagen-like region of C1q in sera of patients with autoimmune rheumatic diseases. Wener MH; Uwatoko S; Mannik M Arthritis Rheum; 1989 May; 32(5):544-51. PubMed ID: 2785797 [TBL] [Abstract][Full Text] [Related]